Global Expansion And Minimally Invasive Care Will Shape Future Progress

Key Takeaways

• Medicare reimbursement and rising clinician adoption are expanding the medical segment, driving ongoing revenue growth and broader integration into hospitals and clinics.
  
• International sales expansion, operational improvements, and demand for minimally invasive solutions are strengthening margins, recurring revenue, and long-term growth prospects.
  
• Ongoing financial losses, slow medical segment adoption, unpredictable international sales, and execution risks threaten Milestone Scientific's long-term revenue growth and ability to achieve profitability.

Catalysts

A biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally.

• Recent Medicare Part B reimbursement approval for the CompuFlo Epidural system in key states has opened a pathway for millions of eligible procedures, enabling broader adoption by pain management clinics and hospitals. As data accrues and clinicians gain confidence, this is poised to drive significant revenue growth and expand the medical segment's share of the business.
  
• The new leadership team, with deep experience in scaling healthcare and medical device operations internationally, is implementing a focused, programmatic approach to commercialization-particularly targeting high-impact domestic and international markets first, which should accelerate top-line growth and improve operational efficiencies, positively impacting margins and earnings.
  
• Direct-to-clinic and e-commerce sales models have increased international dental sales substantially (up by over 100% year-over-year), enabling improved margins, higher customer engagement, and more recurring revenue from consumables, strengthening gross margins and contributing to long-term earnings stability.
  
• The long-term trend toward more minimally invasive, patient-centric healthcare is fueling demand for Milestone Scientific's advanced, pain-free injection solutions, supporting higher adoption rates and revenue potential as these technologies become standard care in both developed and emerging markets.
  
• Expansion into emerging geographies-bolstered by new distribution relationships and operational centers (e.g., direct shipping from China)-positions Milestone to capture upside from growing global healthcare access and the aging population, further supporting long-term sustainable revenue growth.

Milestone Scientific Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Milestone Scientific's revenue will grow by 15.8% annually over the next 3 years.
• Analysts are not forecasting that Milestone Scientific will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Milestone Scientific's profit margin will increase from -44.0% to the average US Medical Equipment industry of 12.1% in 3 years.
• If Milestone Scientific's profit margin were to converge on the industry average, you could expect earnings to reach $1.8 million (and earnings per share of $0.02) by about August 2029, up from -$4.1 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 95.1x on those 2029 earnings, up from -10.4x today. This future PE is greater than the current PE for the US Medical Equipment industry at 26.2x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.5%, as per the Simply Wall St company report.

Risks

• Despite recent revenue growth, Milestone Scientific continues to operate at a net loss ($3.5 million loss from operations for the first half of 2025) and is burning cash ($2.8 million used in operations in six months), with just $1.3 million in cash on hand, creating significant risk of dilution or inability to sustain operations without new fundraising, which may adversely impact earnings and shareholder value.
  
• The company's long-term growth strategy relies heavily on successful adoption and reimbursement for its CompuFlo Epidural system in the medical market, yet as of now, adoption remains extremely limited (5–10 clinics) and progress is slow, indicating potential difficulty scaling this business line and achieving substantial revenue diversification away from the established dental segment.
  
• International sales are characterized as "lumpy" and dependent on large, sporadic distributor orders; this unpredictable revenue pattern, coupled with challenges in distribution expansion and tariff uncertainty in markets like Brazil, risk long-term revenue stability and margin consistency.
  
• There appears to be an ongoing lack of focus and execution risk regarding the medical segment, as prior strategies failed to translate strong clinical validation into widespread adoption; management's new "more disciplined, focused" approach is unproven, and continued operational missteps could suppress both revenue growth and gross margins.
  
• Long-term industry and company trends, including intensifying competition from well-capitalized medical device companies and reliance on a concentrated product portfolio, expose Milestone to risk of product obsolescence, pricing pressures, slower adoption, and squeezed margins-potentially jeopardizing its ability to achieve sustained profitability and positive earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $1.25 for Milestone Scientific based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1.5, and the most bearish reporting a price target of just $1.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $14.6 million, earnings will come to $1.8 million, and it would be trading on a PE ratio of 95.1x, assuming you use a discount rate of 7.5%.
• Given the current share price of $0.49, the analyst price target of $1.25 is 61.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.